Valuation: Scholar Rock Holding Corporation

Market Cap 5.71B 5.02B 4.67B 4.28B 8.04B 550B 8.17B 55.4B 21.65B 270B 21.44B 20.98B 935B P/E 2026 *
-15x
P/E 2027 * -18.7x
Enterprise Value 5.41B 4.75B 4.42B 4.06B 7.62B 521B 7.74B 52.47B 20.5B 256B 20.31B 19.87B 886B EV / Sales 2026 *
831x
EV / Sales 2027 * 35.8x
Free-Float
99.22%
Yield 2026 *
-
Yield 2027 * -
1 day-3.66%
1 week-9.82%
Current month-13.33%
1 month-12.95%
3 months+2.56%
6 months+6.19%
Current year+8.22%
1 week 47.28
Extreme 47.275
51.46
1 month 47.28
Extreme 47.275
58.49
Current year 38.75
Extreme 38.75
58.49
1 year 27.07
Extreme 27.07
58.49
3 years 5.93
Extreme 5.93
58.49
5 years 4.32
Extreme 4.325
58.49
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 27/04/2025
Director of Finance/CFO 62 27/04/2025
Chief Operating Officer 58 27/04/2025
Director TitleAgeSince
Chairman 59 01/07/2017
Director/Board Member 53 01/08/2014
Director/Board Member 78 01/10/2016
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Director

-5,446 0.0047%
01/07/26 Sell

Director

-3,053 0.0027%
01/07/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-3.66%-9.82%+22.39%+606.22% 5.71B
+0.93%+6.97%+59.60%+69.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.46%-1.29%+2.86%+425.15% 23.18B
-2.97%-2.35%-22.53%-15.34% 22.59B
-0.66%+1.52%+21.38%-7.30% 20.46B
-1.34%+0.51%+26.03%-28.68% 17.56B
0.00%+1.98%+34.55%+546.54% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
-0.50%-0.98%+21.43%+179.36% 13.92B
Average -1.19%+0.17%+37.71%+216.73% 24.58B
Weighted average by Cap. -0.87%+1.82%+38.80%+147.69%

Financials

2026 *2027 *
Net sales 6.51M 5.72M 5.32M 4.88M 9.17M 627M 9.31M 63.16M 24.68M 308M 24.45M 23.92M 1.07B 149M 131M 122M 112M 210M 14.39B 214M 1.45B 566M 7.08B 561M 549M 24.47B
Net income -410M -360M -335M -307M -577M -39.45B -586M -3.97B -1.55B -19.4B -1.54B -1.5B -67.07B -356M -313M -291M -267M -502M -34.31B -510M -3.46B -1.35B -16.87B -1.34B -1.31B -58.32B
Net Debt -302M -265M -247M -226M -425M -29.09B -432M -2.93B -1.14B -14.3B -1.13B -1.11B -49.45B -356M -312M -290M -267M -501M -34.24B -508M -3.45B -1.35B -16.83B -1.33B -1.31B -58.21B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
24/07/26 $47.67 -3.66% 838,705
23/07/26 $49.48 +2.44% 1,028,993
22/07/26 $48.30 -5.07% 1,608,162
21/07/26 $50.88 +0.43% 824,450
20/07/26 $50.66 -4.16% 898,227
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
47.67USD
Average target price
59.31USD
Spread / Average Target
+24.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock